Evidence map›Paper›PMID 28700829›Full record

ArticleAnalytical chemistry2017

Fast, Sensitive, and Quantitative Point-of-Care Platform for the Assessment of Drugs of Abuse in Urine, Serum, and Whole Blood.

Ying Li, Uvaraj Uddayasankar, Bangshun He, Ping Wang, Lidong Qin

Abstract read
In one paragraph

Article in Analytical chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Technologies for Frugal and Sensitive Point-of-Care Immunoassays.Annual review of analytical chemistry (Palo Alto, Calif.) · 2022
    Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ying LiDepartment of Nanomedicine, Houston Methodist Research Institute , 6670 Bertner Avenue, Houston, Texas 77030, United States.
Uvaraj UddayasankarDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital , 6670 Bertner Avenue, Houston, Texas 77030, United States.
Bangshun HeDepartment of Nanomedicine, Houston Methodist Research Institute , 6670 Bertner Avenue, Houston, Texas 77030, United States.
Ping WangDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital , 6670 Bertner Avenue, Houston, Texas 77030, United States.
Lidong QinDepartment of Nanomedicine, Houston Methodist Research Institute , 6670 Bertner Avenue, Houston, Texas 77030, United States.ORCID 0000-0002-6608-0600

Funding

Development of a Point-of-Care Volumetric Bar-Chart Chip for Drug QuantitationR01DA035868 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI QIN, LIDONG, WANG, PING · 2013 to 2020
$4.3M
(PQA4) Point-of-Care Test of Exposure to Hepatocellular Carcinoma Risk by V-ChipR01CA180083 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI QIN, LIDONG, WU, XIFENG · 2013 to 2016
$2.1M
Integrative Analysis of Cancer Single-cell Transcriptomic and Functional Proteomic Data (2 of 2)R21CA191179 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI QIN, LIDONG, ZU, YOULI · 2015 to 2017
$774k
Revolutionize Budding-Yeast-Based Aging Study by High-Throughput Lab-on-a-Chip DevicesR56AG049714 · NIA · METHODIST HOSPITAL RESEARCH INSTITUTE · PI DANG, WEIWEI, QIN, LIDONG · 2015 to 2015
$508k
NCI NIH HHS R01 CA180083NCI NIH HHS R21 CA191179NIA NIH HHS R56 AG049714NIDA NIH HHS R01 DA035868
6 · The paper itself

Abstract

Drug abuse is a major public health problem in many countries in Europe and North America. Currently available platforms for drug abuse assessment are facing technical challenges of nonquantitation, inaccuracy, low throughput, incompatibility with diverse complex specimens, long assay times, and requirement of instrument and/or expertise for readout. Here, we report an integrated competitive volumetric-bar-chart chip (CV-Chip) to assay multiple drug targets at the point-of-care (POC). To the best of our knowledge, it is the first time that a POC platform has been demonstrated to fully address the above-mentioned limitations. We applied this integrated CV-chip platform to assay multiple drugs in 38 patient urine and serum samples and validated the on-chip results with an LC-MS/MS method, indicating a clinical sensitivity and specificity of 0.94 and 1.00, respectively. We further demonstrated that the combination of an on-chip blood separator with the CV-Chip enabled the platform to directly assay finger-prick whole blood samples, which have always been recognized as an ideal biospecimen for POC detections. In summary, this integrated CV-Chip is able to serve as a sensitive, accurate, fast, portable, readout visible, and minimally invasive platform for drug abuse assessment.

Indexed as

Lab-On-A-Chip DevicesHumansIllicit DrugsMicrofluidic Analytical TechniquesPoint-of-Care SystemsSensitivity and SpecificityIllicit Drugs

Identifiers

PMID28700829
PMCPMC6398168

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.